Takafumi Nakano, M.D., Ph.D.
ã·ã¹ãã©ãã³æµææ§åŸæ¶²è ºçç幹现èã«å¯ŸããmTORé»å®³å€ã®æçšæ§
mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells
J Dent Res.
2020幎10æ
åŸæ¶²è ºçã¯æå¹ãªååŠçæ³ãååšãããæŸå°ç·çæ³ã«ãæµææ§ã§ããããšãããæªã ã«æè¡ãæ²»çã®äžå¿ã§ãããããããªãããé²è¡åŸæ¶²è ºçã¯é¡é¢ç¥çµæµžæœ€ãé¡é¢ã®éªšæµžæœ€ãé èåºæµžæœ€ãªã©ã«èµ·å ããæè¡å°é£å ŽåãæŽå®¹çãªåé¡ããå®å šåé€å°é£ãªå Žåãå€ããæè¡ã«å ãæŸå°ç·çæ³ãååŠçæ³ãè¿œå ãããããšã床ã ãããããããæè¡ã»æŸå°ç·çæ³ã»ååŠçæ³ãªã©éåŠçæ²»çãè¡ã£ããšããŠããé«æªæ§åºŠåŸæ¶²è ºçã¯é«çã«å±æåçºã»é éåçºããããããããæŸå°ç·çæ³ãé é žéšçååŠçæ³ã®äžå¿ã§ããcisplatinãžã®æµææ§ã®åå ãšããŠç幹现èã®ååšãææãããŠãããæã ã¯ãããŸã§ã«åŸæ¶²è ºçã®äžã§æãé »åºŠã®é«ãçµç¹åã®äžã€ã§ããç²è¡šç®çã®çŽ°èæ ªãäžçã§åããŠæš¹ç«ãããç²è¡šç®ç现èã®äžã«é«ãèªå·±è€è£œèœåã³é è «çèœããã€çŽ°èéå£ïŒç幹现èïŒé«ALDH掻æ§ã»CD44é«çºçŸïŒãåå®ããŠãããæŽã«ããã®ç幹现èã«ãããŠmTORçµè·¯ã掻æ§åãããŠããããšã瀺ããŠããããããã®çµæãããmTORé»å®³è¬ãçšããããšã§æ²»çæµææ§ã®ç幹现èãé»å®³ããcisplatinã®æ²»çå¹æãé«ãŸãã®ã§ã¯ãªãããšèããããŸãã现èé害æ§ã¢ãã»ã€ã«ãŠè€æ°ã®mTORé»å®³å€ã®äžã§temsirolimusãæãæå¹æ§ãé«ããšããçµæãåŸããIn vitroåã³in vivo (æ£è è «ççµç¹ç§»æ€ã¢ãã«)ã«ãããŠãcisplatinã«ããç幹现èæ°ã®å¢å ãmTORçµè·¯ã®æŽ»æ§åãBmi-1ïŒèªå·±è€è£œèœããŒã«ãŒïŒã®çºçŸäº¢é²ãã¹ãã£ã¢åœ¢æèœã®äº¢é²ãèªãããäžæ¹ã§ãtemsirolimusã¯ãin vitroãšin vivoã®ãããã«ãããŠããcisplatinã«ããèªå°ãããç幹现èæ°ã®å¢å ã»mTORçµè·¯ã®æŽ»æ§åã»Bmi-1çºçŸäº¢é²ã®ããããæå¶ããè «çå¢æ®é床ã®æå¶ãèªããã䜵çšçæ³çŸ€ã®äžã§ãç¹ã«temsirolimuså è¡æ²»ç矀ã§ã¯cisplatinå è¡æ²»ç矀ãããåªäœã«å¹æãé«ãã£ããæ¬ç 究ã«ããåŸæ¶²è ºçãcisplatinã«æµææ§ã§ããåå ã®äžã€ãšããŠç幹现èã®ååšã®å¯èœæ§ã瀺ããããæŽã«ãtemsirolimusã¯cisplatinæµææ§ã§ããç幹现èãé»å®³ããtemsirolimusãšcisplatinã®äœµçšçæ³ãé²è¡åŸæ¶²è ºçã«å¯ŸããŠæå¹ã§ããå¯èœæ§ã瀺åãããããŸããtemsirolimusã¯æ¢ã«FDAã§ä»ççš®ã«ãããŠæ¿èªãããŠããè¬å€ã§ãããããæ©æã«èšåºå¿çšããåŸãææãªçµã¿åãããšèããããã
åè³è ã®ã³ã¡ã³ãïŒ
ãã®åºŠã¯ãã®ãããªçŽ æŽãããè³ãé ãã倧å€å æ ã«æããŸãããŸãåãã«ãå šäžçã«åœ±é¿ãåãŒããŠããæ°åã³ãããŠã€ã«ã¹ææçã®åœ±é¿ã§å€§å€ãªäžãUJAè«æè³ã®éå¶ã®å çæ¹ã審æ»å¡ã®å çæ¹ã«æè¬ç³ãäžããŸããæ¬è«æã§ã¯ãæ¯èŒççšãªçŸæ£ã§ããåŸæ¶²è ºçãããŒãã«ç 究ãè¡ããŸãããåŸæ¶²è ºçã¯æè¡ã«ããå®å šæåºä»¥å€ã«æå¹ãªæ²»çæ³ããªããæ¥æ¬ã§èšåºãè¡ã£ãŠããéã«ãåŸæ¶²è ºçã®åçºã»è»¢ç§»çäŸã§çŸè¡æ²»çã®éçãæããããšã床ã ãããŸãããä»åã®è«æã§æããã«ããç幹现èãã¿ãŒã²ãããšããããšã§æ²»çã®å¯èœæ§ãåºããããšãåºæ¥ããšèããŠãããŸããããŸã ãŸã æªè§£æãªéšåãå€ããããæ¬è³åè³ãå±ã¿ã«ãåŒãç¶ãåŸæ¶²è ºçã®ç 究ãç¶ç¶ããŠãããããšæã£ãŠãããŸãã
審æ»å¡ã®ã³ã¡ã³ãïŒ
ä»åãmTORã®é»å®³å€ãšååŠçæ³å€ã·ã¹ãã©ãã³ã䜵çšããããšã§çæ§å¹¹çŽ°èã®å¢æ®é»æ¢ããªãã³ã«ç§»æ€ããŠã¹ã¢ãã«ã§ã®çã®éçž®ã瀺ãããšã«æåãããmTORã®é»å®³å€ãšããŠãã§ã«FDAã§ä»ã®çã®æ²»çã«æ¿èªãããŠããååç©ã䜿çšããã®ã§ãæ©æã®èšåºå¿çšãæåŸ ããããïŒäžåå çïŒ
mTORé»å®³å€ãåŸæ¶²ç·ããã«å¯ŸããååŠçæ³ãšçµã¿åããããšããæ²»çæ³ã®å®éšçæ ¹æ ãäœã£ãããšã§ãèšåºå¿çšã«ãè²¢ç®ããå¯èœæ§ããããŸããïŒå°éå çïŒ
ãšããœãŒãïŒ
æ¬è«æã«ãããŠç 究éå§ãã1幎åã¯æ¯èŒçã¹ã ãŒãºã§ãã£ããšæããŸãããšããããä»ã®ç 究è
åæ§ã«æ°åã³ããææçæ¡å€§ã«äŒŽãç 究宀ééã§ã2020幎3æããã¯ç 究ãå®å
šã«æ¢ãŸã£ãŠããŸããŸãããééã«äŒŽããåœåè¡ãäºå®ã§ãã£ãããŠã¹ã®å®éšã¯äžæ¢ããããåŸãªãç¶æ³ã«ãªã£ãŠããŸããŸããããããããããŸã§ã«ç 究宀ã®ã¡ã³ããŒã«ååããŠããããªããèšç»çã«ç 究ãé²ããŠããããããªããšã2幎ãšããçåŠæéäžã«è«æããŸãšããããšãåºæ¥ãŸãããä»åã®ããšã§ãåç¬ã§ã¯ãªãç 究宀å
šäœãšããŠèšç»çã«ç 究ããããšã®å€§åããšãäžæž¬ã®äºæ
ãžã®å¯Ÿå¿ãäœéšããããšãã§ããä»åŸã®èªåèªèº«ã«ãšã£ãŠéåžžã«è¯ãçµéšã§ãã£ããšæããŸãã